ResearcherUniversity of California, Los AngelesNo recent work listed
Krisztina Kisfalvi
Matched on OpenAlex author ID A5074928602. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2013: 3 papers
Papers 3
- Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. First author DOI 10.1016/j.bbrc.2012.11.010↗
- Metformin inhibits the growth of human pancreatic cancer xenografts. Co-author DOI 10.1097/mpa.0b013e31827aec40↗
- Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0057289↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- James W. Sinnett‐Smith · 3 shared papers, 2013 · strength 0.15
- Paper Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on gl… DOI 10.1016/j.bbrc.2012.11.010↗
- Paper Metformin inhibits the growth of human pancreatic cancer xenografts. DOI 10.1097/mpa.0b013e31827aec40↗
- Paper Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metform… DOI 10.1371/journal.pone.0057289↗
- Enrique Rozengurt · 3 shared papers, 2013 · strength 0.15
- Paper Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on gl… DOI 10.1016/j.bbrc.2012.11.010↗
- Paper Metformin inhibits the growth of human pancreatic cancer xenografts. DOI 10.1097/mpa.0b013e31827aec40↗
- Paper Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metform… DOI 10.1371/journal.pone.0057289↗
- Heloisa Prado Soares · 1 shared paper, 2013 · strength 0.05
- Guido Eibl · 1 shared paper, 2013 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.